Trametinib is a selective MEK1/2 kinase inhibitor indicated, in combination with the BRAF inhibitor dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations or in the adjuvant setting of V600E- or V600K-positive melanomas. This evidence concerns the gene BRAF and melanoma.